Pulmonary Biomarker Surfactant Protein-B Is Used for Diagnosis
|
By LabMedica International staff writers Posted on 10 Dec 2008 |
|
Roche Diagnostics (Rotkreuz, Switzerland) and an Australian Biotech company, Southern Medical Diagnostics (SMD; Walkerville, Australia) signed licensing agreements on diagnostic applications of Surfactant Protein-B.
According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.
A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.
Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.
"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."
Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.
Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.
Related Links:
Roche Diagnostics
Southern Medical Diagnostics
According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.
A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.
Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.
"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."
Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.
Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.
Related Links:
Roche Diagnostics
Southern Medical Diagnostics
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Latest Molecular Diagnostics News
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
- Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
- AI Tool Improves Long-Read Detection of Cancer Mutations
- FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
- Blood Gene Expression Fluctuates More Than Expected Over Time
- Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
- Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
- Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more
Hematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Pathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Partnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more
